Integrated Filing — IndAS

General information about company
Scrip Code	532523
NSE Symbol	BIOCON
MSEI Symbol	NOTLISTED
ISIN	INE376G01013
Name of company	BIOCON LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	08-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	02-Apr-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical
Start date and time of board meeting	08-May-2025   17:00:00
End date and time of board meeting	08-May-2025   17:55:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-01-30
Indicate Company website link for updated RPT policy of the Company	https://www.biocon.com/docs/Policy-on-Related-Party-Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Not Applicable

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	6438000000	22426000000
	Other income	627000000	2423000000
	Total income	7065000000	24849000000
2	Expenses
(a)	Cost of materials consumed	3224000000	10854000000
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-60000000	-546000000
(d)	Employee benefit expense	1243000000	5013000000
(e)	Finance costs	567000000	2369000000
(f)	Depreciation, depletion and amortisation expense	330000000	1278000000
(f)	Other Expenses
1	Others	1428000000	5478000000
2	Recovery of cost from co-development partners (net)	-17000000	-131000000
	Total other expenses	1411000000	5347000000
	Total expenses	6715000000	24315000000
3	Total profit before exceptional items and tax	350000000	534000000
4	Exceptional items	0	6075000000
5	Total profit before tax	350000000	6609000000
6	Tax expense
7	Current tax	265000000	306000000
8	Deferred tax	-127000000	210000000
9	Total tax expenses	138000000	516000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	212000000	6093000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	212000000	6093000000
17	Other comprehensive income net of taxes	-36000000	-124000000
18	Total Comprehensive Income for the period	176000000	5969000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	6003000000	6003000000
	Face value of equity share capital	5	5
27	Details of debt securities
22	Reserves excluding revaluation reserve		109241000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.18	5.09
	Diluted earnings (loss) per share from continuing operations	0.18	5.09
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	0.18	5.09
	Diluted earnings (loss) per share from continuing and discontinued operations	0.18	5.09
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		Pleaserefertotheoutcomeofboardmeetingfiledon08may2025

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	10038000000
	Capital work-in-progress	6867000000
	Investment property	540000000
	Goodwill	0
	Other intangible assets	557000000
	Intangible assets under development	146000000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	113826000000
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	1657000000
	Total non-current financial assets	115483000000
	Deferred tax assets (net)	0
	Other non-current assets	878000000
	Total non-current assets	134509000000
2	Current assets
	Inventories	8363000000
	Current financial asset
	Current investments	0
	Trade receivables, current	8294000000
	Cash and cash equivalents	2495000000
	Bank balance other than cash and cash equivalents	3000000
	Loans, current	0
	Other current financial assets	1347000000
	Total current financial assets	12139000000
	Current tax assets (net)
	Other current assets	1200000000
	Total current assets	21702000000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	156211000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	6003000000
	Other equity	109241000000
	Total equity attributable to owners of parent	115244000000
	Non controlling interest
	Total equity	115244000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	22515000000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	35000000
	Total non-current financial liabilities	22550000000
	Provisions, non-current	333000000
	Deferred tax liabilities (net)	136000000
	Deferred government grants, Non-current
	Other non-current liabilities	576000000
	Total non-current liabilities	23595000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	6195000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	627000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	7517000000
	Total Trade payable	8144000000
	Other current financial liabilities	1365000000
	Total current financial liabilities	15704000000
	Other current liabilities	267000000
	Provisions, current	345000000
	Current tax liabilities (Net)	1056000000
	Deferred government grants, Current	0
	Total current liabilities	17372000000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	40967000000
	Total equity and liabilites	156211000000
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block
Textual Information(1)	Pleaserefertotheoutcomeofboardmeetingfiledon08may2025

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will not be reclassified to profit or loss	-48000000	-19000000
	Total Amount of items that will not be reclassified to profit and loss	-48000000	-19000000
2	Income tax relating to items that will not be reclassified to profit or loss	-20000000	26000000
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified to profit or loss	-10000000	-105000000
	Total Amount of items that will be reclassified to profit and loss	-10000000	-105000000
4	Income tax relating to items that will be reclassified to profit or loss	-2000000	-26000000
5	Total Other comprehensive income	-36000000	-124000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			6609000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			2369000000
	Adjustments for decrease (increase) in inventories			-1716000000
	Adjustments for decrease (increase) in trade receivables, current			2108000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			309000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			3582000000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			0
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			1278000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			10000000
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			0
	Adjustments for dividend income			0
	Adjustments for interest income			47000000
	Adjustments for share-based payments			400000000
	Adjustments for fair value losses (gains)			-1897000000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-6438000000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			70000000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			28000000
	Net cash flows from (used in) operations			6637000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			426000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			6211000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			6832000000
	Other cash payments to acquire equity or debt instruments of other entities			17475000000
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			0
	Purchase of property, plant and equipment			3174000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			46000000
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			2852000000
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			302000000
	Interest received			450000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			6073000000
	Net cash flows from (used in) investing activities	-9890000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			99000000
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			5580000000
	Repayments of borrowings			0
	Payments of lease liabilities			23000000
	Dividends paid			600000000
	Interest paid			108000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			4948000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			1269000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			3000000
	Net increase (decrease) in cash and cash equivalents			1272000000
	Cash and cash equivalents cash flow statement at beginning of period			1223000000
	Cash and cash equivalents cash flow statement at end of period			2495000000